# HARMONi-2 (NCT05499390)

> AK112 in Advanced Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05499390
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Akeso
- Conditions: Advanced Non-small-cell Lung Cancer
- Interventions: AK112; Pembrolizumab
- Enrollment: 398
- Primary outcome: PFS assessed by IRRC per RECIST v1.1

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

The commentary discusses ivonescimab versus pembrolizumab in first-line PD-L1-positive advanced NSCLC, including the PD-1/VEGF approach and subgroup interpretation. Speakers raise whether pembrolizumab monotherapy is an appropriate comparator for PD-L1-low disease, whether overall survival should be a primary endpoint, and whether findings from the China-only study translate beyond that setting. Discussion also covers control-arm limitations, censoring, toxicity, predictive biomarkers, and whether the data should change practice pending global-trial evidence.

## Indexed commentary on HARMONi-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 136
- YouTube: 9
- Podcasts: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=harmoni-2-nct05499390

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05499390", "email": "<work email>"}; the inbox owner confirms by the emailed link.